



The Global Language of Business

# Clinical Trial Request For Inventory Report Business Message Standard (BMS)

*Release 3.5.1, Draft, Jan 2022*



## Document Summary

Document Item	Current Value
Document Name	Clinical Trial Request For Inventory Report Business Message Standard (BMS)
Document Date	Jan 2022
Document Version	3.5.1
Document Issue	1
Document Status	Draft

## Work Request Reference

Date of WR Submission to GSMP:	WR Submitter(s):	Refer to Work Request (WR) Number(s):

## Business Requirements Document (BRAD) Reference

BRAD Title	BRAD Issue Date	BRAD Version

## Document Change History

Date of Change	Version	Changed By	Reason for Change	Summary of Change
3-Apr-2020	BMS 3.4.2	Mark Van Eeghem	Initial Draft	Initial Draft
10-Aug-2020	BMS 3.4.2	Piergiorgio Licciardello	Change after workgroup revision	Structure changes, classes and attributes definitions
24-Sep-2020	BMS 3.4.2	Piergiorgio Licciardello	Group revision	
14-Oct-2020	BMS 3.4.2	Piergiorgio Licciardello	Updates after community revision	
29-Oct-2020	BMS 3.4.2	Piergiorgio Licciardello	Errata corrige	Class diagram update
15-Jan-2021	BMS 3.5 – Issue 1	Miklos Bolyky	BMS Release 3.5	See summary of changes
05-Jan-2022	BMS 3.5.1 – Issue 1	Miklos Bolyky	BMS Release 3.5.1	See summary of changes

## Disclaimer

GS1®, under its IP Policy, seeks to avoid uncertainty regarding intellectual property claims by requiring the participants in the Work Group that developed this **Clinical Trial Request For Inventory Report Business Message Standard (BMS)** to agree to grant to GS1 members a royalty-free licence or a RAND licence to Necessary Claims, as that term is defined in the GS1 IP Policy. Furthermore, attention is drawn to the possibility that an implementation of one or more features of this Specification may be the subject of a patent or other intellectual property right that does not involve a Necessary Claim. Any such patent or other intellectual property right is not subject to the licencing obligations of GS1. Moreover, the agreement to grant licences provided under the GS1 IP Policy does not include IP rights and any claims of third parties who were not participants in the Work Group.

Accordingly, GS1 recommends that any organization developing an implementation designed to be in conformance with this Specification should determine whether there are any patents that may encompass a specific implementation that the organisation is developing in compliance with the Specification and whether a licence under a patent or other intellectual property right is needed. Such a determination of a need for licencing should be made in view of the details of the specific system designed by the organisation in consultation with their own patent counsel.

THIS DOCUMENT IS PROVIDED "AS IS" WITH NO WARRANTIES WHATSOEVER, INCLUDING ANY WARRANTY OF MERCHANTABILITY, NONINFRINGEMENT, FITNESS FOR PARTICULAR PURPOSE, OR ANY WARRANTY OTHERWISE ARISING OUT OF THIS SPECIFICATION. GS1 disclaims all liability for any damages arising from use or misuse of this Standard, whether special, indirect, consequential, or compensatory damages, and including liability for infringement of any intellectual property rights, relating to use of information in or reliance upon this document.

GS1 retains the right to make changes to this document at any time, without notice. GS1 makes no warranty for the use of this document and assumes no responsibility for any errors which may appear in the document, nor does it make a commitment to update the information contained herein.

GS1 and the GS1 logo are registered trademarks of GS1 AISBL.

# Table of Contents

<b>1</b>	<b>Business Domain View .....</b>	<b>5</b>
1.1	Introduction .....	5
1.2	References .....	5
<b>2</b>	<b>Business Context .....</b>	<b>6</b>
<b>3</b>	<b>Business Transaction View .....</b>	<b>6</b>
<b>4</b>	<b>Business Information View .....</b>	<b>8</b>
4.1	Clinical Trial Request For Inventory Report .....	8
4.2	Enumerations (message specific) .....	11
4.3	Code Lists .....	11
<b>5</b>	<b>Business Message Examples .....</b>	<b>11</b>
5.1	Example 1 .....	11
<b>6</b>	<b>Implementation Considerations.....</b>	<b>12</b>
6.1	User Guide .....	12
6.2	Message Specific Considerations .....	12
<b>7</b>	<b>Summary of Changes .....</b>	<b>12</b>
7.1	BMS Release 3.4.2 .....	12
7.2	BMS Release 3.5 .....	13
7.3	BMS Release 3.5.1 .....	13
<b>8</b>	<b>Appendices .....</b>	<b>13</b>
<b>9</b>	<b>Acknowledgements.....</b>	<b>13</b>
9.1.1	Work Group .....	13
9.1.2	Development Team Members .....	15

# 1 Business Domain View

## 1.1 Introduction

### Purpose

The Request for Inventory Report communicates a request for provision of an inventory report, which gives current information about inventory levels. The inventory report request is related to finished products as identified GTINs.

This Request for Inventory Business Message Standard is one part of a suite of documents designed to provide the detailed technical mappings to GS1 message formats for EDI messages being implemented for Clinical Trials.

The other documents in this suite are:

- Inventory Release
- Shipment Request
- Shipment Notification
- Shipment Confirmation
- Despatch Advice
- Receiving Advice
- Inventory Report
- Kit Status Change
- Dispensing Advice

### Scope

The scope of this work includes all messages identified in [the GS1 Pharmaceutical Clinical Trial Electronic Messaging Standard Implementation Guideline](#), hereafter called 'the Guideline', section 4.2.

### Considerations

The workgroup that developed this mapping document has ensured that the messages and associated mappings are technology and sponsor agnostic.

It is important that organisations implementing electronic business messaging in line with this guideline undertake an appropriate assessment to ensure that the blinding status of the trial is respected in the messages exchanged.

Messaging communications with transport providers / couriers / carriers are out of scope because there are already electronic processes in place and altering them would not add value.

## 1.2 References

Reference Name	Description
<a href="#">GS1 Pharmaceutical Clinical Trial Electronic Messaging Standard Implementation Guideline</a> ,	The guideline details the business requirement of the clinical trials context, both in terms of process design and data set shared between the actors


## 2 Business Context

Context Category	Value(s)
Industry	Healthcare, Pharmaceuticals & Medical Devices
Geopolitical	All
Product	All
Process	Clinical Trials
System Capabilities	GS1 System
Official Constraints	None

## 3 Business Transaction View

### Business Process Participants

As detailed in *the Guideline*, section 4.1, the diagram and table below provide an overview of the main actors involved in the process.



**Table 3-1** Roles and responsibilities

Role	Responsibility in process
Manufacturer/sponsor	Has overall responsibility for the trial, and produces the Investigational Product (IP)
Contract Manufacturing Organisation (CMO)	Manufactures and may package IP and IP kits at the direction of the manufacturer / sponsor
Packaging site	Packages and labels the IP and IP kits
Distributor (with warehouse)	Warehouses and distributes the IP kits as needed to the sites
Carrier (transporting the goods)	Logistics provider moving the IP kits at the request of other stakeholders
Clinical trial site	The healthcare provider location where the trial is conducted and dispensing to the patient typically occurs
Return facility	Responsible for receipt of any IP kits returned from trial sites
Distribution Management Entity (DME)	A term used to identify the system(s) managing, distribution, and disposition of clinical supplies. In many cases this is the

	interactive technology IRT system, portal, a set of tools or different databases used to share information during a clinical trial, etc.
--	--

### Use Case Diagram

N/A

### Use Case Description

Below is the use case detailed in *the Guideline*, section 7.8.

Performance goals	A request to drive the subsequent action of sending an inventory report.						
Preconditions	Unique identification of locations, trade items and logistics units will be undertaken. Correct identification receiver (Ship To/inventory location) are in place.						
Postconditions	None identified						
Scenario	<p>Begins when the sponsor sends a message to ask for inventory levels from across the supply chain.</p> <p>Continues with...</p> <table><tr><th>Step #</th><th>Actor</th><th>Activity step</th></tr><tr><td>1</td><td>Receiver</td><td>Receives communication.</td></tr></table> <p>Ends when the Receiver takes action to provide inventory level information.</p>	Step #	Actor	Activity step	1	Receiver	Receives communication.
Step #	Actor	Activity step					
1	Receiver	Receives communication.					
Alternative scenario	Not applicable						
Related requirements	None identified						
Related rules	None identified						

### Activity Diagram(s)

Not applicable


### Sequence Diagram(s)

Not applicable

## 4 Business Information View

### 4.1 Clinical Trial Request For Inventory Report

#### Class diagram





## Global Data Dictionary (GDD) report

Content	Attribute / Role	Datatype / Secondary class	Multiplicity	Definition	Constraints
<b>ClinicalTrialRequestForInventory Report</b>				The Request for Inventory Report communicates a request for provision of an inventory report, which gives current information about inventory levels. The inventory report request is related to finished products as identified GTINs.	
ASSOCIATION	GENERALIZATION	EcomDocument	1..1		
ASSOCIATION	requestForInventoryReportIdentification	Ecom_EntityIdentification	1..1	The unique identification of the inventory request	
ASSOCIATION	sender	Ecom_PartyIdentification	1..1	The sender of the request, usually the sponsor or the DME	
ASSOCIATION	receiver	Ecom_PartyIdentification	1..1	The organization in charge of the physical sites where items are located	
ASSOCIATION		InventoryReportRequestInformation	1..*	The set of parameters necessary to identify the items for which the inventory is requested	
ATTRIBUTE	protocolID	string	1..1	The unique identifier of the protocol	{1..20}
ATTRIBUTE	protocolOwner	GLN	1..1	The identification of the sponsor of the protocol	
<b>InventoryReportRequestInformation</b>					
ASSOCIATION	inventoryReportingPartyLocation	Ecom_PartyIdentification	1..1	The GLN of the physical location for which the inventory is requested	
ASSOCIATION	inventoryReportingParty	Ecom_PartyIdentification	0..1	The GLN of the entity reporting the inventory when different from the receiver of the request in the header	
ATTRIBUTE	investigationalProductIdentification	gtin	1..1	The GTIN of the investigational product	

Content	Attribute / Role	Datatype / Secondary class	Multiplicity	Definition	Constraints
ATTRIBUTE	kitIdentification	string	1..1	The identification of the kit (usually serial+GTIN or protocol number)	{1..200}
ATTRIBUTE	kitType	string	1..1	The medication type (ACTIVE, PLACEBO)	{1..200}
ATTRIBUTE	inventoryReportingDateTime	DateTime	0..1	The reference date of the requested inventory	



**Note:** Reference Shared Common Library Business Message (BMS) Release 3.5.1 and eCom Domain Common Library Business Message (BMS) Release 3.5.1 for all common information.

## 4.2 Enumerations (message specific)

Not applicable.

## 4.3 Code Lists

Class	Codelist	GDD Link



**Note:** Refer to the Global Data Dictionary (GDD) for the code values.

# 5 Business Message Examples

## 5.1 Example 1

### Party Information

GS1 Global Location Number	Party Type
9520000000004	Sponsor
9520000000011	Sender - DME
9520000000127	Receiver - Organization receiving the request
9520000000028	Kit Location

### Message Example 1

Attribute	Value
<b>ClinicalTrialRequestForInventoryReport</b>	
<b>requestForInventoryReportIdentification</b>	
entityIdentification	10
<b>sender</b>	
GLN	9520000000011
<b>receiver</b>	
GLN	9520000000127
protocolID	PROT1
protocolOwner	9520000000004
<b>InventoryReportRequestInformation</b>	
<b>InventoryReportingPartyLocation</b>	
GLN	9520000000028
investigationalProductIdentification	9520000000530
kitIdentification	9520000000280001
kitType	PLACEBO

Attribute	Value
inventoryReportingDateTime	2020-08-22T00:00:00.000


## 6 Implementation Considerations

### 6.1 User Guide

All implementation considerations are discussed in [the GS1 Pharmaceutical Clinical Trial Electronic Messaging Standard Implementation Guideline](#).

### 6.2 Message Specific Considerations

The detail section of the message includes the list of the specific kits for which the inventory status is required



## 7 Summary of Changes

Any change in the GS1 standards is done based on the Work Request (WR) submitted by the GS1 User Companies or Member Organisations. All Work Requests are documented in the Work Request system available on the GS1 website: <http://wr.gs1.org>. The system is accessible to registered users. New visitors need to register first, to be able to access it. WRs can be searched by the number referenced in tables below, see: Search Work Requests. The number starts with the two last digits of the year when it was submitted, followed by the consecutive number within that year.



**Note:** WRs submitted earlier than February 2012 should be searched in Old Change Requests.

### 7.1 BMS Release 3.4.2

Change	Associated CR Number
<ul style="list-style-type: none"> <li>Initial Draft</li> </ul>	

## 7.2 BMS Release 3.5

No work requests. Indirect changes due to upgrade to new Shared and eCom Common libraries.

## 7.3 BMS Release 3.5.1

No work requests. Indirect changes due to upgrade to new Shared and eCom Common libraries.

## 8 Appendices

Not Applicable

## 9 Acknowledgements

### 9.1.1 Work Group

Function	Name	Company / organisation
<b>WG chair</b>	Olivia Chauvel (Chair)	CH Victor Dupouy
<b>WG chair</b>	Pierre Fernandez-Barbureau (Chair)	SANOFI
<b>WG chair</b>	Hans von Steiger (Chair)	Pfizer
<b>WG member</b>	Jean-Michel Descoutures	International Hospital Federation (IHF)
<b>WG member</b>	Feargal Mc Groarty	St. James's Hospital
<b>WG member</b>	Vincent Puglia	endpoint clinical
<b>WG member</b>	Mike Meakin	DHL
<b>WG member</b>	Sylvain Alberola	SANOFI
<b>WG member</b>	Céline Bordes-Terrier	CREAPHARM
<b>WG member</b>	Giedré Bracaité	F. Hoffmann-La Roche Ltd.
<b>WG member</b>	Doris Cadart	SANOFI
<b>WG member</b>	Pedro Carvalho	Ipsen
<b>WG member</b>	Robert Giguere	AbbVie
<b>WG member</b>	Nicolas Gryspeert	F. Hoffmann-La Roche Ltd.
<b>WG member</b>	Michael Hoefling	Boehringer Ingelheim Pharma GmbH & Co.KG
<b>WG member</b>	Richard Hwang	Pfizer
<b>WG member</b>	Marco Inserra	CSL Behring GmbH
<b>WG member</b>	Jason James	Bristol-Myers Squibb
<b>WG member</b>	Matthias Kallmeyer	Boehringer Ingelheim Pharma GmbH & Co.KG
<b>WG member</b>	Nicolas Le Rudlier	CREAPHARM
<b>WG member</b>	Yann Montcourt	Ipsen
<b>WG member</b>	Barry Moore	GlaxoSmithKline
<b>WG member</b>	Marianne Perdrijat	DBV TECHNOLOGIES
<b>WG member</b>	Amy Rupp	CSL Behring GmbH
<b>WG member</b>	Amanda Scott	Biogen
<b>WG member</b>	Jodi Smith-Gick	Eli Lilly and Company

Function	Name	Company / organisation
<b>WG member</b>	Richard Austin	PAREXEL International GmbH
<b>WG member</b>	Nick Bobrinskoy	nCoup, Inc.
<b>WG member</b>	Arpad Boldis	Deloitte
<b>WG member</b>	Robert Celeste	Center for Supply Chain Studies
<b>WG member</b>	Dilip Daswani	Qliktag Software (formally Zeebric LLC)
<b>WG member</b>	Andreas Geissler	PAREXEL International GmbH
<b>WG member</b>	Mark Hanly	Almac Clinical Technologies
<b>WG member</b>	Mike Hutton	Almac Clinical Technologies
<b>WG member</b>	Kelly Knowles	Bracket Global
<b>WG member</b>	Jitendra Kumar	Thermo Fisher Scientific
<b>WG member</b>	Cherish Lallone	McCreadie Group
<b>WG member</b>	Charlotte Meuldermans	Deloitte
<b>WG member</b>	Fabiana Monaco	PAREXEL International GmbH
<b>WG member</b>	Josef Preishuber-Pflügl	CISC Semiconductor GmbH
<b>WG member</b>	Theodora Sarver	Almac Clinical Technologies
<b>WG member</b>	Michael schlesselman	McCreadie Group
<b>WG member</b>	Colette Thorold	PAREXEL International GmbH
<b>WG member</b>	Elizabeth Waldorf	TraceLink
<b>WG member</b>	Stefan Zietze	PAREXEL International GmbH
<b>WG member</b>	Andrea Zobel	PAREXEL International GmbH
<b>WG member</b>	Shreenidhi Bharadwaj	Syndigo
<b>WG member</b>	Tony Zhang	Syndigo
<b>WG member</b>	Richard Perkins	eClinical Forum
<b>WG member</b>	Olivier Mary	COLCA Medical & Scientific
<b>WG member</b>	Poppy Abeto Kiese	GS1 Austria
<b>WG member</b>	Andrea Arozamena	GS1 Mexico
<b>WG member</b>	Mahdi Barati	GS1 Iran
<b>WG member</b>	Jiraporn Chalermjirarat	GS1 Thailand
<b>WG member</b>	Shawn Chen	GS1 Thailand
<b>WG member</b>	Mignone Cheng	GS1 Hong Kong, China
<b>WG member</b>	Luiz Costa	GS1 Brasil
<b>WG member</b>	Sandra Couto	GS1 Canada
<b>WG member</b>	Jesper Kervin Franke	GS1 Denmark
<b>WG member</b>	Stefan Gathmann	GS1 Ireland
<b>WG member</b>	Nicole Golestani	GS1 Canada
<b>WG member</b>	Rami Habbal	GS1 UAE
<b>WG member</b>	Michaela Hähn	GS1 Germany
<b>WG member</b>	Christine Horvath-Hanko	GS1 Hungary
<b>WG member</b>	Anna Klapper	GS1 Germany
<b>WG member</b>	Catherine Koetz	GS1 Australia
<b>WG member</b>	Anne-Claire Krid	GS1 France

Function	Name	Company / organisation
<b>WG member</b>	Camille Labeaune	GS1 France
<b>WG member</b>	Ildikó Lieber	GS1 Hungary
<b>WG member</b>	Valerie Marchand	GS1 France
<b>WG member</b>	Adrien Molines	GS1 France
<b>WG member</b>	Zubair Nazir	GS1 Canada
<b>WG member</b>	Alice Nguyen	GS1 Vietnam
<b>WG member</b>	James Perng	GS1 Chinese Taipei
<b>WG member</b>	James Perng	GS1 Chinese Taipei
<b>WG member</b>	Paul Reid	GS1 UK
<b>WG member</b>	Sylvia Reingardt	GS1 Germany
<b>WG member</b>	Sue Schmid	GS1 Australia
<b>WG member</b>	Julian Sin	GS1 Hong Kong, China
<b>WG member</b>	Mig Smith	GS1 UK
<b>WG member</b>	Peter Sturtevant	GS1 US
<b>WG member</b>	Flora Sue	GS1 China
<b>WG member</b>	Sarah Torrance	GS1 UK
<b>WG member</b>	Koichi Uemura	GS1 Japan
<b>WG member</b>	Amber Walls	GS1 US
<b>WG member</b>	Connie Wong	GS1 Canada
<b>WG member</b>	Pete Alvarez	GS1 Global Office
<b>WG member</b>	Jean-Luc Champion	GS1 Global Office
<b>WG member</b>	Steven Keddie	GS1 Global Office
<b>WG member</b>	Neil Piper	GS1 Global Office
<b>WG member</b>	Greg Rowe	GS1 Global Office
<b>WG member</b>	Tania Snioch	GS1 Global Office

### 9.1.2 Development Team Members

Function	Name	Organisation
GSMP Process Lead	David Buckley	GS1 Global Office
Technical Development Lead	Miklós Bolyky	GS1 Global Office
Peer Review	Mark Van Eeghem	GS1 Global Office